Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domatinostat + Pembrolizumab in Refractory Melanoma
NCT03278665Phase 2Completed
- Sponsor
- 4SC AG
- Start
- Sep 2017
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Domatinostat in cutaneous melanoma (CM), sponsored by 4SC AG. Primary endpoint: Incidence of Adverse Events up to 114 weeks. Started Sep 2017; status: completed.
02
Drugs
Domatinostat
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT03278665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278665.